nach oben

Erschienen in:

05.10.2019 | Melasma | derma aktuell

Von Hydrochinon bis PRP

Neue Therapien der Hyperpigmentierung am Horizont?

verfasst von: Dr. Miriam Sonnet

Erschienen in: ästhetische dermatologie & kosmetologie | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Zusammenfassung

Goldstandard für die Behandlung von Pigmentunregelmäßigkeiten der Haut ist nach wie vor Hydrochinon. Aber auch andere Therapien, wie plättchenreiches Plasma, sind in Sicht — deren Wirksamkeit muss sich allerdings in weiteren Studien zeigen.

Bayerl C. Dermokosmetika gegen Hyperpigmentierungen — Vorstellung einer neuen Leitlinie der GD. 22. GD Jahrestagung, 12. März 2018 in Berlin http://www.gd-online.de/german/veranstalt/images2018/22.GD_JT_2018_ABSTRACTS_WH_TEIL_2_C_Bayerl.pdf

Brenner M, Berking C. Grundlagen der Hautpigmentierung. Der Hautarzt. 2010; 61: 554–60 CrossRef

Bayerl C. Behandlung von Hyperpigmentierungen. ästhetische dermatologie & kosmetologie. 2015; 7: 30–35 CrossRef

Becker S et al. Melasma. Der Hautarzt. 2017; 68: 120–6 CrossRef

Filoni A et al. Melasma: How hormones can modulate skin pigmentation. J Cosmet Dermatol. 2019; 18: 458–63 CrossRef

Kwon SH. Melasma: Updates and perspectives. Exp Dermatol. 2019; 28: 704–8 CrossRef

Giménez García RM, Carrasco Molina S. Drug-Induced Hyperpigmentation: Review and Case Series. J Am Board Fam Med. 2019; 32: 628–38 CrossRef

Davis EC, Callender VD. Postinflammatory hyperpigmentation: a review of the epidemiology, clinical features, and treatment options in skin of color. J Clin Aesthet Dermatol. 2010; 3: 20–31 PubMedPubMedCentral

Roberts WE. Pollution as a risk factor for the development of melasma and other skin disorders of facial hyperpigmentation is there a case to be made? J Drugs Dermatol. 2015; 14: 337–41 PubMed

10.

Vierkötter A et al. Airborne particle exposure and extrinsic skin aging. J Invest Dermatol. 2010; 130: 2719–26 CrossRef

11.

Ferreira Cestari T et al. A comparison of triple combination cream and hydroquinone 4% cream for the treatment of moderate to severe facial melasma. J Cosmet Dermatol. 2007; 6: 36–9 CrossRef

12.

Ahmad Nasrollahi S, Sabet Nematzadeh M, Samadi A, Ayatollahi A, Yadangi S, Abels C et al. Evaluation of the safety and efficacy of a triple combination cream (hydroquinone, tretinoin, and fluocinolone) for treatment of melasma in Middle Eastern skin. Clin Cosmet Investig Dermatol. 2019; 12: 437–44 CrossRef

13.

Jarratt M. Mequinol 2%/tretinoin 0.01% solution: an effective and safe alternative to hydroquinone 3% in the treatment of solar lentigines. Cutis. 2004; 74: 319–22 PubMed

14.

Monteiro RC et al. A Comparative Study of the Efficacy of 4% Hydroquinone vs 0.75% Kojic Acid Cream in the Treatment of Facial Melasma. Indian J Dermatol. 2013; 58: 157 CrossRef

15.

Deo KS et al. Kojic Acid vis-a-vis its Combinations with Hydroquinone and Betamethasone Valerate in Melasma: A Randomized, Single Blind, Comparative Study of Efficacy and Safety. Indian J Dermatol. 2013; 58: 281–5 CrossRef

16.

Mazurek K, Pierzchała E. Comparison of efficacy of products containing azelaic acid in melasma treatment. J Cosmet Dermatol. 2016; 15: 269–82 CrossRef

17.

Dayal S et al. Combination of glycolic acid peel and topical 20% azelaic acid cream in melasma patients: efficacy and improvement in quality of life. J Cosmet Dermatol. 2017; 16: 35–42 CrossRef

18.

Kirsch B et al. Evaluating the Efficacy, Safety, and Tolerability of the Combination of Tazarotene, Azelaic Acid, Tacrolimus, and Zinc Oxide for the Treatment of Melasma: A Pilot Study. J Clin Aesthet Dermatol. 2019; 12: 40–5 PubMedPubMedCentral

19.

Pekmezci E. A novel triple combination in treatment of melasma: Significant outcome with far less actives. J Cosmet Dermatol. 2019; https://doi.org/10.1111/jocd.12904

20.

Hollinger JC et al. Are Natural Ingredients Effective in the Management of Hyperpigmentation? A Systematic Review. J Clin Aesthet Dermatol. 2018; 11: 28–37 PubMedPubMedCentral

21.

Ertam I et al. Efficiency of ellagic acid and arbutin in melasma: a randomized, prospective, open-label study. J Dermatol. 2008; 35: 570–4 CrossRef

22.

Makino ET et al. Evaluation of a hydroquinone-free skin brightening product using in-vitro inhibition of melanogenesis and clinical reduction of ultraviolet-induced hyperpigmentation. J Drugs Dermatol. 2013; 12: s16–s20 PubMed

23.

Griffiths CE et al. Topical tretinoin (retinoic acid) improves melasma. A vehicle-controlled, clinical trial. Br J Dermatol. 1993; 129: 415–21 CrossRef

24.

Hegyi V, Hegyi J. Methoden und Mittel zur Pigmentierung und Depigmentierung. Der Hautarzt. 2010; 61: 586–92 CrossRef

25.

Rivas S, Pandya AG. Treatment of Melasma with Topical Agents, Peels and Lasers: An Evidence-Based Review. Am J Clin Dermatol. 2013; 14: 359–76 CrossRef

26.

Iraji F et al. Efficacy of mesotherapy with tranexamic acid and ascorbic acid with and without glutathione in treatment of melasma: A split face comparative trial. J Cosmet Dermatol. 2019; https://doi.org/10.1111/jocd.12874

27.

Choi S et al. Aloesin inhibits hyperpigmentation induced by UV radiation. Clin Exp Dermatol. 2002; 27: 513–5 CrossRef

28.

Zubair S, Mujtaba G. Comparison of efficacy of topical 2% liquiritin, topical 4% liquiritin and topical 4% hydroquinone in the management of melasma. Journal of Pakistan Association of Dermatologists. 2009; 19: 158–63

29.

Draelos ZD. A split-face evaluation of a novel pigment-lightening agent compared with no treatment and hydroquinone. J Am Acad Dermatol. 2015; 72: 105–7 CrossRef

30.

Alvin G et al. A comparative study of the safety and efficacy of 75% mulberry (Morus alba) extract oil versus placebo as a topical treatment for melasma: a randomized, single-blind, placebo-controlled trial. J Drugs Dermatol. 2011; 10: 1025–31 PubMed

31.

Castanedo-Cazares JP et al. Topical niacinamide 4% and desonide 0.05% for treatment of axillary hyperpigmentation: a randomized, double-blind, placebo-controlled study. Clin Cosmet Investig Dermatol. 2013; 6: 29–36 CrossRef

32.

Janney MS et al. A Randomized Controlled Study Comparing the Efficacy of Topical 5% Tranexamic Acid Solution versus 3% Hydroquinone Cream in Melasma. J Cutan Aesthet Surg. 2019; 12: 63–7 PubMedPubMedCentral

33.

Zhu CY et al. Analysis of the effect of different doses of oral tranexamic acid on melasma: a multicentre prospective study. Eur J Dermatol. 2019; 29: 55–8 PubMed

34.

Colferai MMT et al. Evaluation of oral tranexamic acid in the treatment of melasma. J Cosmet Dermatol. 2018; https://doi.org/10.1111/jocd.12830

35.

Padhi T, Pradhan S. Oral Tranexamic Acid with Fluocinolone-Based Triple Combination Cream Versus Fluocinolone-Based Triple Combination Cream Alone in Melasma: An Open Labeled Randomized Comparative Trial. Indian J Dermatol. 2015; 60: 520 PubMedPubMedCentral

36.

Wattanakrai P et al. Low-fluence Q-switched neodymium-doped yttrium aluminum garnet (1,064 nm) laser for the treatment of facial melasma in Asians. Dermatol Surg. 2010; 36: 76–87 CrossRef

37.

Imhof L et al. A Prospective Trial Comparing Q-Switched Ruby Laser and a Triple Combination Skin-Lightening Cream in the Treatment of Solar Lentigines. Dermatol Surg. 2016; 42: 853–7 CrossRef

38.

Abdel-Raouf Mohamed H et al. Comparative study of fractional Erbium: YAG laser vs combined therapy with topical steroid as an adjuvant treatment in melasma. J Cosmet Dermatol. 2019; 18: 517–23 CrossRef

39.

Merchán WH et al. Platelet-rich plasma, a powerful tool in dermatology. J Tissue Eng Regen Med. 2019; 13: 892–901 CrossRef

40.

Hofny ERM et al. Platelet-rich plasma is a useful therapeutic option in melasma. J Dermatolog Treat. 2019; 30: 396–401 CrossRef

41.

Cayırlı M et al. Regression of melasma with platelet-rich plasma treatment. Ann Dermatol. 2014; 26: 401–2 CrossRef

42.

Ellabban NF et al. Efficacy and tolerability of using platelet-rich plasma versus chemical peeling in periorbital hyperpigmentation. J Cosmet Dermatol. 2019; https://doi.org/10.1111/jocd.12964

43.

Arrowitz C et al. Effective Tyrosinase Inhibition by Thiamidol Results in Significant Improvement of Mild to Moderate Melasma. J Invest Dermatol. 2019; 139: 1691–1698.e6 CrossRef

44.

Sarkar R et al. Role of broad-spectrum sunscreen alone in the improvement of melasma area severity index (MASI) and Melasma Quality of Life Index in melasma. J Cosmet Dermatol. 2019; 18: 1066–73 PubMed

45.

Grimes PE et al. New oral and topical approaches for the treatment of melasma. Int J Womens Dermatol. 2018; 5: 30–6 CrossRef

46.

Jacobus Berlitz S et al. Azelaic acid-loaded nanoemulsion with hyaluronic acid - a new strategy to treat hyperpigmentary skin disorders. Drug Dev Ind Pharm. 2019; 45: 642–50 CrossRef

47.

Phacharapiyangkul N et al. Effect of Sucrier Banana Peel Extracts on Inhibition of Melanogenesis through the ERK Signaling Pathway. Int J Med Sci. 2019; 16: 602–6 CrossRef

48.

Mansouri P et al. Evaluation of the efficacy of cysteamine 5% cream in the treatment of epidermal melasma: a randomized double-blind placebo-controlled trial. Br J Dermatol. 2015; 173: 209–17 CrossRef

49.

Adalatkhah H, Sadeghi-Bazargani H. The first clinical experience on efficacy of topical flutamide on melasma compared with topical hydroquinone: a randomized clinical trial. Drug Des Devel Ther. 2015; 9: 4219–25 PubMedPubMedCentral

50.

Gheisari M et al. The efficacy and safety of topical 5% methimazole vs 4% hydroquinone in the treatment of melasma: A randomized controlled trial. J Cosmet Dermatol. 2019; https://doi.org/10.1111/jocd.12987

51.

Jo DJ et al. Human skin-depigmenting effects of resveratryl triglycolate, a hybrid compound of resveratrol and glycolic acid. Int J Cosmet Sci. 2018; https://doi.org/10.1111/ics.12458

52.

Ryu JH et al. A study of the human skin-whitening effects of resveratryl triacetate. Arch Dermatol Res. 2015; 307: 239–47 CrossRef

Titel: Von Hydrochinon bis PRP
Neue Therapien der Hyperpigmentierung am Horizont?
verfasst von: Dr. Miriam Sonnet
Publikationsdatum: 05.10.2019
Verlag: Springer Medizin
Schlagwörter: Melasma
Hyperpigmentierung
Erschienen in: ästhetische dermatologie & kosmetologie / Ausgabe 5/2019
Print ISSN: 1867-481X
Elektronische ISSN: 2198-6517
DOI: https://doi.org/10.1007/s12634-019-0092-x

Neu im Fachgebiet Dermatologie

29.05.2023 | Fetale und neonatale Infektionen | Nachrichten

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Hauptrubriken

Service

Fachgebiete

Themen

Sammlungen

Springer Medizin

Neue Therapien der Hyperpigmentierung am Horizont?

Zusammenfassung

Neu im Fachgebiet Dermatologie

Perinatale HPV-Übertragung in der Schwangerschaft scheint eher selten vorzukommen

Formal rechtmäßiger Regress kann gleichwohl rechtsmissbräuchlich sein

Bei schlechter Luft steigt die Zahl der Neurodermitisfälle

Immuntherapie: besser morgens

Update Dermatologie

Hauptrubriken Chevron down icon Chevron up icon

Service Chevron down icon Chevron up icon

Fachgebiete Chevron down icon Chevron up icon

Themen Chevron down icon Chevron up icon

Sammlungen Chevron down icon Chevron up icon

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2019

Doppelt stark für ein jugendliches Aussehen

Lichturtikaria nach Schweregrad effizient behandeln

adk Beitrittsantrag

Dr. Google — Konkurrent oder Kollege?

Fachärzte beim budgetfreien Honorar für ein Jahr in der Zwickmühle

Update zur frontal fibrosierenden Alopezie

Neu im Fachgebiet Dermatologie

Perinatale HPV-Übertragung in der Schwangerschaft scheint eher selten vorzukommen

Formal rechtmäßiger Regress kann gleichwohl rechtsmissbräuchlich sein

Bei schlechter Luft steigt die Zahl der Neurodermitisfälle

Immuntherapie: besser morgens

Update Dermatologie

Hauptrubriken

Service

Fachgebiete

Themen

Sammlungen